462 Results (Page 1 of 19)
Spain Markets Research Reports
Spain Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Analysis
Spain Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing awareness and diagnosis, Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS), unmet medical needs, advancements in drug development, Regulatory Approvals of drugs like eculizumab, inebilizumab and satralizumab , rising healthcare expenditure and growing collaborations in research and development of drugs are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).
Spain Herpes Simplex Virus Therapeutics Market Analysis
Spain Herpes Simplex Virus Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Herpes simplex virus (HSV) is a common viral infection that can cause a range of diseases in humans. High Prevalence of HSV Infections, Increasing Awareness and Diagnosis, Continued research and development efforts, Technological advancements and Increasing healthcare expenditure, particularly in developed countries, provides a supportive environment for the growth of the HSV Therapeutics market. Social stigma surrounding herpes, Drug-resistant HSV strains provided by limited treatment options are restraining factors in herpes simplex therapeutics market. GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Novartis AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd. Are global key players in herpes simplex therapeutics market.
Spain COVID-19 Clinical Trials Market Analysis
This report presents a strategic analysis of the Spain COVID-19 Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Spain COVID-19 Clinical Trials Market, offering unmatched value, accuracy and expert insights.
Spain Dental Consumables Market Analysis
The Spain Dental Consumables Market was valued at $652.3 Mn in 2023 and is projected to grow at a CAGR of 7.0% from 2023 to 2023, to $1047.5 Mn by 2030. The key drivers of this industry growing dental care needs, technological advancements, expanding dental infrastructure, increasing disposable incomes, public health initiatives, dental tourism, rising consumption of sugary and starchy foods, rise in unhealthy eating habits due to rising urbanization, and changing living standards. The industry is primarily dominated by players such as Dentaid, Phibo, Klockner Implant System, Dentsply Sirona, 3M, Henry Schein, and Ivoclar Vivadent Dental among others.
Spain Dental Caries Detectors Market Analysis
The Spain Dental Caries Detectors Market was valued at $4.4 Mn in 2023 and is predicted to grow at a CAGR of 7.9% from 2023 to 2030, to $7.5 Mn by 2030. Spain Dental Caries Detectors Market is growing due to Increasing Dental Awareness and Education, Prevalence of dental caries, and Advanced imaging and diagnostics. The market is primarily dominated by players such as Smile 360, Pacific Dental Services, Dental Services Group, Sirona Dental Systems, Dentsply Sirona, KaVo Kerr, Ivoclar Vivadent, and Planmeca.
Spain Clinical Nutrition for Diabetes Care Market Analysis
The Spain Clinical Nutrition for Diabetes Care Market was valued at $41.50 Mn in 2023 and is predicted to grow at a CAGR of 3.78% from 2023 to 2030, to $53.80 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Mediquo, Sweetcare, Pfizer Inc., and Mefood Omics among others.
Spain Pharmacy Automation Device Market Analysis
The Spain Pharmacy Automation Device Market was valued at $106.2 Mn in 2023 and is predicted to grow at a CAGR of 8.9% from 2023 to 2030, to $192.8 Mn by 2030. Spain Pharmacy Automation Device Market is growing due to Increasing Demand for Efficiency, Adoption of Electronic Health Records, Increasing adoption among end-users. The market is primarily dominated by players such as KUKA AG, Parata Systems LLC, Dickinson, and Company, Talyst Systems, LLC, Becton, ScriptPro LLC, RxSafe, LLC, Capsa Healthcare, McKesson Corporation; Pearson Medical Technologies, Baxter; Talyst, LLC, Scriptpro LLC, Becton Dickinson and Company, Fulcrum Pharmacy Management, Inc.
Spain Cardiac Pacemakers Market Analysis
The Spain Cardiac Pacemakers Market was valued at $78.11 Mn in 2023 and is predicted to grow at a CAGR of 2.2% from 2023 to 2030, to $90.96 Mn by 2030. The key drivers of this industry include an aging population, advancements in technology, and healthcare expenditure. The industry is primarily dominated by players such as Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic among others.
Spain Lysosomal Storage Disease Therapeutics Market Analysis
Spain lysosomal storage disease therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The rise in lysosomal diseases, greater public awareness of unusual lysosomal storage disorders, increased research and development for diagnostics, and increased drug development for treating lysosomal diseases are the main drivers impacting the market for lysosomal storage disease treatments. Major global players in this market are Pfizer Inc, Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi (Genzyme Corporation), BioMarin, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, Sigilon Therapeutics, Inc, and Orphazyme A/S are some of the companies that participate in this industry.
Spain Interstitial Cystitis Therapeutics Market Analysis
Spain Interstitial Cystitis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 30. The global market is expanding as a result of a rise in the frequency of interstitial cystitis and support for research. Major global players in this market are Amneal Pharmaceuticals Inc, Astellas Pharma Inc, Aurobindo Pharma Ltd, Bayer AG, Cadila Healthcare Ltd, Eli Lilly and Co, Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd, Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd, Mission Pharmacal Co, Perrigo Co. Plc, Pfizer Inc, Purdue Pharma LP, Seikagaku Corp, Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Viatris Inc.
Spain Hypophosphatasia (HPP) Therapeutics Market Analysis
Spain hypophosphatasia (HPP) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for hypophosphatasia is anticipated to grow as a result of an increase in the ailment's prevalence, a family history of it, a robust product pipeline, and increased financing for research to create cutting-edge, new treatments for the condition. Major global players in the hypophosphatasia therapeutic market are Kirin Holdings Company Limited, Vericel Corporation, Mereo Biopharma Group Plc., Novartis AG, AM-Pharma B.V., Bayer AG, Pfizer Inc, Ultragenyx Pharmaceutical Inc, BioMarin Pharmaceutical Inc, Prior Company Ltd, Enobia Pharma Corporation, AstraZeneca Plc, Rallybio Corporation.
Spain Hypertrophic Cardiomyopathy Therapeutics Market Analysis
Spain hypertrophic cardiomyopathy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. In addition to heart diseases, the market for therapies for hypertrophic cardiomyopathy is primarily driven by rises in the frequency of obesity and sedentary behaviour. Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., and Bayer AG are a few of the businesses now dominating the global hypertrophic cardiomyopathy therapeutics market.
Spain Von Willebrand Disease Therapeutics Market Analysis
Spain Von Willebrand Disease Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Some of the key factors influencing market growth include the introduction of new von Willebrand disease therapies, rising awareness of the condition due to an increase in government initiatives and awareness campaigns, and expanding partnerships and collaborations between top research institutions and regulatory bodies. Major global players in Von Willebrand Disease Therapeutics Market are Octapharma AG Grifols, S.A. Shire plc Bayer AG CSL Behring Pfizer, Inc. Akorn, Inc. Ferring B.V.
Spain Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Spain Clinical Nutrition for Chronic Kidney Diseases Market was valued at $30.30 Mn in 2023 and is predicted to grow at a CAGR of 5.03% from 2023 to 2030, to $42.70 Mn by 2030. The key drivers of this industry include the high prevalence of CKD, increasing awareness and education, and technological advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Spain Insulin Market Analysis
This report presents a strategic analysis of the Spain Insulin Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Spain Insulin Market, offering unmatched value, accuracy and expert insights.
Spain Sanfilippo Syndrome (MPS-III) Therapeutics Market Analysis
Spain Sanfilippo Syndrome (MPS-III) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sanfilippo Syndrome (MPS-III) Therapeutics is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global Sanfilippo Syndrome (MPS-III) Therapeutics market.
Spain Pseudomonas Aeruginosa Infection Therapeutics Market Analysis
Spain Pseudomonas Aeruginosa Infection Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Industry income is expected to increase as a result of increased pseudomonas aeruginosa infections, an ageing population, future innovative antibiotic formulations, an increase in patients, and greater public awareness of the infection. Major global players in Pseudomonas Aeruginosa Infection Therapeutics Market are Allergan, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc, Merck & Co.
Spain Primary Hyperoxaluria (PH) Therapeutics Market Analysis
Spain Primary Hyperoxaluria (PH) Therapeutics Market is projected to grow from $3.5 Mn in 2022 to $6.34 Mn by 2030, registering a CAGR of 7.7% during the forecast period of 2022-2030. One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Therapeutics Market are Allena Pharmaceuticals, Inc., Intellia Therapeutics, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
Spain Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis
Spain Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc
Spain Paroxysmal Noctural Hemglobinuria (PNH) Therapeutics Market Analysis
Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Paroxysmal Nocturnal Hemoglobinuria Therapeutics is being driven by reasons like the rise in blood and bone marrow abnormalities, population ageing, rising disposable income, unmet demand for PNH treatment, and technological improvements in stem cell transplantation. Major global players in Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market are Achillion Pharmaceuticals Akari Therapeutics Alexion Pharmaceuticals Amgen Inc. Apellis Pharmaceuticals F. Hoffmann-La Roche AG. GE Healthcare Johnson & Johnson Ra Pharmaceuticals Regeneron Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited (Shire Plc) Thermo Fisher Scientific Inc.
Spain Clinical Nutrition for Cancer Care Market Analysis
The Spain Clinical Nutrition for Cancer Care Market was valued at $108.7 Mn in 2023 and is predicted to grow at a CAGR of 4.04% from 2023 to 2030, to $143.4 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the Spain Clinical Nutrition for Cancer Care Market are Fresenius Kabi España, Baxter España, and Clinical Nutrition SAU, among others.
Spain Gram-Negative Infection Therapeutics Market Analysis
The Spain Gram-Negative Infection Therapeutics Market was valued at $287.1 Mn in 2023 and is predicted to grow at a CAGR of 4.9% from 2023 to 2030 to $401.3 Mn by 2030. Factors fuelling this market expansion include the aging population, heightened research and development efforts, and the increasing prevalence of gram-negative infections. Leading companies in this market include Sanofi, Novartis, Baxter, Takeda, and others.
Spain Home Infusion Therapy Market
The Spain Home Infusion Therapy Market was valued at $694 Mn in 2023 and is predicted to grow at a CAGR of 7.1% from 2023 to 2030, to $1121.8 Mn by 2030. The key drivers of the market include rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. The prominent players of the Spain Home Infusion Therapy Market are Becton, Dickinson and Company (BD), Baxter International, ICU Medical (Smiths Medical), and Fresenius Kabi, among others.
Spain Hepatitis A Therapeutics Market Analysis
The Spain Hepatitis A Therapeutics Market was valued at $14.23 Mn in 2023 and is predicted to grow at a CAGR of 1.2% from 2023 to 2030 to $15.27 Mn by 2030. Significant factors driving this market include the rising prevalence of Hepatitis A in Spain, the growing vulnerable population, and Spain's global health initiatives. Leading companies in this sector, such as F. Hoffmann-La Roche Ltd. and Grifols, play significant roles.
Spain Non Alcoholic Steatohepatitis (NASH) Therapeutics Market Analysis
Spain Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022-2030. A number of factors, including the rising prevalence of non-alcoholic steatohepatitis, the rising incidence of chronic illnesses linked to it, the rising adoption of sedentary lifestyles, the rising awareness of health issues, etc., have contributed to the growth of the non-alcoholic steatohepatitis market over the past few years. Major global players in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market are Intercept Pharmaceuticals, Inc. Novartis AG,Siemens Healthineers AG, AstraZeneca PLC, Galectin Therapeutics Inc., GENFIT S.A., Madrigal Pharmaceuticals, Inc., Inventiva S.A., ONE WAY LIVER, S.L., Galmed Pharmaceuticals Ltd., Cirius Therapeutics, Prometheus Laboratories Inc., BioPredictive.